On February 8, Loma Linda University Health (LLUH) announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. The goal of ACTIV-2 is to find treatments that can keep people with COVID-19 from getting sicker and requiring hospitalization. People living […] Source: https://atoday.org/loma-linda-university-health-announces-study-of-combination-monoclonal-antibody-treatment-for-early-covid-19/